Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Combination index of apoptosis

From: α-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73

   Combination indexa
Cell line α-TEA:drugb ED50 ED75 ED90 Mean ± SDc  
DOXO       
   MDA-MB-231 20:1 0.48 0.40 0.35 0.41 ± 0.07 Synergismd
   BT-20 20:1 0.48 0.52 0.58 0.53 ± 0.05 Synergism
CDDP       
   MDA-MB-231 2:1 0.55 0.44 0.36 0.45 ± 0.10 Synergism
   BT-20 4:1 0.68 0.74 0.84 0.75 ± 0.08 Synergism
  1. MDA-MB-231 and BT-20 breast cancer cells were treated with different concentrations of α-TEA, doxorubicin (DOXO), and cisplatin (CDDP) alone and in combination for 24 hours. Apoptosis was determined using annexin V-FITC/PI staining/fluorescence-activated cell sorter assay as described in Material and methods. aFor each combination treatment, a combination index was calculated using commercially available software (Calcusyn; Biosoft, Manchester, UK). bThe ratio for the concentrations used in combination treatments was determined from the data in Figure 1. cThe mean ± standard deviation (SD) calculated from the combination index values of the effective dose in 50% (ED50), the effective dose in 75% (ED75) and the effective dose in 90% (ED90) of the population. dCombination index value: <1.0, synergism; 1.0, additive effect; >1.0, antagonism.